Handelsbanken Fonder
ACRS icon

Handelsbanken Fonder’s Aclaris Therapeutics ACRS Stock Holding History

Handelsbanken Fonder’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,800
Closed -$120K – 1568
2023
Q1 		$120K Hold
14,800
– – ﹤0.01% 1518
2022
Q4 		$233K Buy
+14,800
New +$238K ﹤0.01% 1371
2022
Q2 		– Sell
-13,800
Closed -$238K – 1610
2022
Q1 		$238K Hold
13,800
– – ﹤0.01% 1594
2021
Q4 		$201K Buy
+13,800
New +$209K ﹤0.01% 1708

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Handelsbanken Fonder's ACRS Position: Q2 2023 in Review

Handelsbanken Fonder sold out of Aclaris Therapeutics (ACRS) in Q2 2023, closing a stake of 14,800 shares — an estimated $120K sold.

Handelsbanken Fonder first reported a position in ACRS in Q4 2021 and held it in 4 quarters. The position peaked at $238K in Q1 2022. 133 funds tracked by Wall St. Rank hold ACRS as of Q2 2023.

  • Handelsbanken Fonder reported no remaining Aclaris Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Handelsbanken Fonder sold 14,800 Aclaris Therapeutics shares in Q2 2023, an estimated $120K.
  • Handelsbanken Fonder first reported a position in Aclaris Therapeutics in Q4 2021 and held it in 4 quarters.
  • Handelsbanken Fonder's Aclaris Therapeutics position peaked at $238K in Q1 2022.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2023.

Based on Handelsbanken Fonder's 13F filing for Q2 2023, filed 2 Aug 2023.